Researchers from Centre National de la Recherche Scientifique, Inserm, Université Claude Bernard and Université Jean Monnet have synthesized peptides acting as amyloid-β (Aβ) protein aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, cerebral amyloid angiopathy, Down syndrome, Parkinson's disease, Alzheimer's disease and motor neuron disease.
Korea Research Institute of Chemical Technology has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) and mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) inhibitors reported to be useful for the treatment of Parkinson's disease, viral infection, cancer, tuberculosis and non-alcoholic steatohepatitis.
Triple-negative breast cancer (TNBC) is the most aggressive breast tumor subtype and despite treatment advances, still has shorter median overall survival rates and higher recurrence and metastatic rates than other subtypes, due to resistance to chemotherapy.
Researchers from Nagoya City University presented the development of a new mouse model with cholinergic dysfunction and amyloid pathogenesis for Alzheimer's disease.
Carisma Therapeutics Inc. has received FDA clearance of its IND application for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor (CAR)-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).
Pemphigus vulgaris is an autoimmune skin disease mediated by autoantibodies to desmoglein-3 (DSG3). Since the adult murine model of this disease is quite limited, researchers aimed to develop a novel active adult pemphigus vulgaris murine model.
Researchers from Karolinska Institutet and collaborators have reported on the characterization of novel human anti-CD44v6 antibodies aimed to be used as anticancer agents in the radiotherapy of CD44v6-expressing cancers.
Vidac Pharma Holding plc has announced results from an in vitro study of VDA-1275 in combination with chemotherapeutic agents to treat solid tumors. VDA-1275 is a potent small molecule that reverses cancer cell hyper glycolytic metabolism (Warburg effect).
A mouse line with severe haploinsufficiency of about 92% reduction in coiled-coil and C2 domain-containing protein 1A (CC2D1A) expression was generated by breeding of Cc2d1a-knockout allele with C2d1a -/V5-HA mice to generate a compound heterozygous murine model of autism spectrum disorder (ASD).
RSS
